Seizure Management in Brain Tumor Patients

Initial Management Approach

The American College of Neurology recommends starting anticonvulsant therapy immediately in brain tumor patients who have experienced seizures following surgery complicated by venous infarct, with the goal of achieving seizure control 1, 2, 3, 4
The majority of brain tumor patients who experience a seizure should be placed on anticonvulsant secondary prophylaxis, at least transiently, according to the American Academy of Neurology 2, 5

Levetiracetam is the preferred first-choice agent for seizure control in brain tumor patients due to its efficacy and overall good tolerability, as recommended by the National Comprehensive Cancer Network 1, 2, 6
Levetiracetam lacks enzyme-inducing properties, avoiding drug interactions with steroids and cytotoxic agents commonly used in brain tumor patients, as noted by the American Society of Clinical Oncology 2, 3
Levetiracetam has no increased bleeding risk, which is particularly relevant given the venous infarct complication, according to the American Heart Association 6

Lamotrigine is a suitable alternative for seizure control in brain tumor patients, with good antiseizure activity, although it requires several weeks to reach therapeutic levels, as recommended by the American Epilepsy Society 1, 2, 3
Lacosamide may serve as add-on treatment if monotherapy fails, according to the National Institute of Neurological Disorders and Stroke 1, 6
Valproic acid is still a viable option for seizure control, but its use is cautioned against in females of childbearing potential due to teratogenicity, as warned by the Food and Drug Administration 1, 2, 6

Enzyme-inducing anticonvulsants, such as phenytoin, phenobarbital, and carbamazepine, should be avoided in brain tumor patients due to their side-effect profile and significant drug interactions with steroids and cytotoxic agents, as recommended by the American College of Neurology 1, 2, 3

Anticonvulsant therapy should be continued until local control is achieved, and tapering can be considered within weeks after surgery if near gross total resection was achieved without recurrent tumor growth, according to the National Comprehensive Cancer Network 2, 3, 4

Seizure occurrences should be questioned at each follow-up visit, and serum drug levels should be considered to assess compliance and explore failure to control seizures, as recommended by the American Academy of Neurology 1, 4
Repeat MRI should be obtained if seizures worsen, as this often heralds tumor progression, according to the American College of Radiology 2, 5
Nonconvulsive status epilepticus should be ruled out with EEG if there are worsening neurological symptoms or vigilance problems, as recommended by the American Clinical Neurophysiology Society 4, 7

Prophylactic anticonvulsants should not be used in brain tumor patients who have not had seizures, as primary prophylaxis is not indicated, according to the American College of Neurology 2, 8
Valproic acid should be avoided in women of childbearing age due to teratogenicity, as warned by the Food and Drug Administration 1, 6
Psychiatric side effects, such as mood changes and behavioral disturbances, should be monitored when using levetiracetam, as recommended by the American Psychiatric Association 1
Drug interactions should be checked regularly if using valproic acid or other agents, according to the American Society of Health-System Pharmacists 1, 6